University General Hospital of Patras
Pátrai, Greece
8 recruiting
Showing 1–17 of 17 trials
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Primary Biliary Cholangitis
Ipsen424 enrolled65 locationsNCT06447168
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled253 locationsNCT05899608
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Systemic Sclerosis (SSc)
argenx81 enrolled74 locationsNCT06655155
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
Takeda268 enrolled194 locationsNCT06233461
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Takeda207 enrolled141 locationsNCT06254950
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Not Applicable
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.
Infection, BacterialInfection Prevention
PENTA Foundation3,080 enrolled24 locationsNCT05993442
Recruiting
Not Applicable
Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF
Atrial Fibrillation (AF)Atrioventricular BlockPacemaker Therapy+1 more
University Hospital of Patras244 enrolled1 locationNCT07250529
Recruiting
Phase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (IPF)
Vicore Pharma AB360 enrolled117 locationsNCT06588686
Recruiting
Phase 3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals550 enrolled166 locationsNCT06435429
Recruiting
Phase 2
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Multiple Myeloma, Refractory
Karyopharm Therapeutics Inc127 enrolled16 locationsNCT04414475
Recruiting
Phase 3
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda59 enrolled52 locationsNCT06747351
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135
Recruiting
Not Applicable
Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension
Brain IschemiaKetamineMagnesium Sulfate+6 more
University General Hospital of Patras150 enrolled1 locationNCT07181564
Recruiting
Phase 2
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Non-small Cell Lung Cancer
Innate Pharma70 enrolled30 locationsNCT05742607